Sign in
4

Changes in Ownership

Axsome Therapeutics, Inc. Filed Acc 0001193125-26-174415

Chief Commercial Officer sold 7,500 shares at $182.42 ($1,368,150)

  • Chief Commercial Officer acquired 7,500 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Maizel Ari · Chief Commercial Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2026-04-22 Exercise or conversion : show line 1 in the form 10b5-1 +7,500 $70.73 $530,475 7,500 D
2026-04-22 Sale : show line 2 in the form 10b5-1 −7,500 $182.42 $1,368,150 0 D
Open-market sales · 7,500 sh · avg $182.42 · $1,368,150

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-04-22 Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (Right to Buy) −7,500 23,710 D
Loading xslF345X06/ownership.xml…